Clinical trial
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to…
NCT00028327 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00028327 |
|---|---|
| Title | Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care |
| Official title | Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz, Lamivudine, Zidovudine |
| Enrollment | 250 |
| Primary completion | Jul 1, 2004 |
| First posted | Dec 21, 2001 |
| Last update posted | Mar 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: